LXG.V - LexaGene Holdings Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.4700
+0.0100 (+2.17%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.4600
Open0.4600
Bid0.4600 x 0
Ask0.4700 x 0
Day's Range0.4600 - 0.4700
52 Week Range0.4300 - 1.0000
Volume107,955
Avg. Volume303,356
Market Cap40.274M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    LexaGene Appoints Dr. Eleanor Kolossovski to Director of Product Marketing

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Dr. Eleanor Kolossovski to the role of Director of Product Marketing. Dr. Kolossovski will help lead the development and execution of LexaGene’s go-to-market strategy for the LX Analyzer, as well as build brand awareness and thought leadership to propel significant growth opportunities in clinical diagnostics, veterinary diagnostics, food safety testing, and other applied market segments.

  • GlobeNewswire

    LexaGene Appoints Steven Armstrong to Senior Director of Operations

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Mr. Steven Armstrong to the role of Senior Director of Operations to oversee the Company’s submission for FDA Emergency Use Authorization of its commercial technology and other regulatory approvals, as well as to institute quality systems for manufacturing. Mr. Armstrong has spent his career leading numerous teams in the commercialization of complex medical devices, directly overseeing global operations including design, development, manufacturing and service operations in eight countries.

  • GlobeNewswire

    LexaGene Provides Update on the Exercise of Warrants

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announces that it has received proceeds from the exercise of warrants. LexaGene is pleased to report that over the past 90 days the Company has received CAD $2.8 million through the exercise of 4.3 million warrants.

  • GlobeNewswire

    LexaGene Provides Corporate Update

    LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides the following corporate update on the development of its commercial technology and information on how the Company has responded to the demand for its technology in view of the COVID-19 outbreak. In response to the COVID-19 outbreak, the World Health Organization has declared a ‘Public Health Emergency of International Concern’ and the FDA has encouraged CLIA labs and IVD manufacturers to submit applications for Emergency Use Authorization (EUA) to help address the lack of quality diagnostics to fight this disease.

  • Coronavirus Highlights Need for Rapid Testing of Pathogens -- SECFilings.com
    Newsfile

    Coronavirus Highlights Need for Rapid Testing of Pathogens -- SECFilings.com

    Seattle, Washington--(Newsfile Corp. - March 9, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how LexaGene Holdings Inc. (OTCQB: LXXGF) (TSXV: LXG) is focused on making testing for pathogens quicker and easier than ever before.A California woman was identified, on February 26, 2020, as the first U.S. resident to contract the coronavirus (COVID-19) from an unknown source. ...

  • GlobeNewswire

    LexaGene’s LX Analyzer Successfully Detects Coronavirus RNA using the CDC’s Tests

    BEVERLY, Mass., Feb. 20, 2020 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for.

  • Newsfile

    LexaGene Discusses The Company's 2020 Commercialization Strategy with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - January 28, 2020) - The Stock Day Podcast welcomed LexaGene Holdings Inc. (OTCQB: LXXGF) ("the Company"), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. CEO and Founder of the Company, Dr. Jack Regan, joined Stock Day host Everett Jolly. Dr. ...

  • GlobeNewswire

    LexaGene’s Analyzer is Designed to Detect Pathogens such as the Novel Coronavirus to Help Avert a Pandemic

    BEVERLY, Mass., Jan. 27, 2020 -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for.

  • GlobeNewswire

    Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has expanded its number of validated tests for antibiotic resistance and has completed testing different superbug isolates provided by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank.

  • LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years
    Simply Wall St.

    LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    LexaGene Announces Closing of CAD$6.64 Million Financing

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has closed its previously announced offering of units (the “Units”) for aggregate gross proceeds of CAD$6.64 million (the “Offering”). The Company issued 12,769,626 Units at a price of CAD$0.52 per Unit, each Unit consisting of one common share of the Company (a “Share”) and one common share purchase warrant, with each warrant entitling the holder to purchase one Share at the price of CAD$0.75 per Share until October 29, 2022. The Offering was conducted by Industrial Alliance Securities Inc. (the “Agent”).

  • CNW Group

    LexaGene Holdings Announces Filing of Final Prospectus

    BEVERLY, MA, Oct. 22, 2019 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed and received a receipt for a final short form prospectus (the "Prospectus") dated October 21, 2019 with the securities regulatory authorities in each of the provinces of Canada, except the Province of Quebec, in connection with the previously announced marketed offering of units (the "Units") of a minimum amount of C$3,500,000 and a maximum of C$10,000,000 at the price of C$0.52 per Unit (the "Offering"). The Offering is being conducted on a "best efforts" agency basis by Industrial Alliance Securities Inc., the Company's agent for the Offering in Canada (the "Agent"). The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and applicable state laws and in such other jurisdictions outside of Canada and the United States as agreed between the Company and the Agent.

  • GlobeNewswire

    LexaGene Holdings Announces Pricing of Prospectus Offering

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce today the pricing of its marketed public offering, which was previously announced in a press release dated September 24, 2019 (the “Offering”). The Company will offer a minimum of 6,730,770 units of the Company (each a “Unit”) and a maximum of 19,230,769 Units at the price of $0.52 per Unit for minimum gross proceeds of approximately $3,500,000 and maximum gross proceeds of approximately $10,000,000. Each Unit is comprised of one common share in the capital of the Company (a “Unit Share”) and one common share purchase warrant (a “Warrant”).

  • How Much Of LexaGene Holdings Inc. (CVE:LXG) Do Insiders Own?
    Simply Wall St.

    How Much Of LexaGene Holdings Inc. (CVE:LXG) Do Insiders Own?

    Every investor in LexaGene Holdings Inc. (CVE:LXG) should be aware of the most powerful shareholder groups. Insiders...

  • GlobeNewswire

    LexaGene Holdings Announces Proposed Offering of Units and Filing of Preliminary Prospectus

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except the Province of Quebec, in connection with a proposed marketed offering of units (the “Units”) of a minimum amount of C$3,500,000 and a maximum of C$10,000,000 (the “Offering”). Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”), each Warrant entitling the holder to purchase one Common Share.

  • GlobeNewswire

    LexaGene Reports on Successful Results from Beta Testing in Human Clinical Diagnostics Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has completed beta testing with Assurance Scientific Laboratories (ASL) in Vestavia, Alabama.  ASL is a certified reference laboratory specializing in providing clinical testing results to physicians nationwide.

  • GlobeNewswire

    LexaGene Develops Test for Deadly Mosquito-borne EEE Virus

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers that can rapidly detect pathogens and other molecular markers, announced today the development of a test for detection of the deadly, Eastern Equine Encephalitis (EEE) virus on its LX technology platform. EEE virus can be transmitted through the bite of an infected mosquito, and has recently caused fatal infections in Michigan, Massachusetts and Rhode Island.

  • GlobeNewswire

    LexaGene Announces its Second Hemp-Cannabis Reference Testing Laboratory as a Beta Test Site

    TSX-V: LXG) (“LexaGene”) or the (“Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today plans to place its LX Analyzer beta unit into ProVerde Laboratories, Inc. (“ProVerde”), one of the largest hemp-cannabis testing reference laboratories in Massachusetts. ProVerde Laboratories is one of three independent laboratories accredited by the state of Massachusetts to test hemp and cannabis products for contaminants such as pesticides and pathogens including bacteria, mold, or other dangerous microorganisms.

  • GlobeNewswire

    LexaGene Reports on Beta Results from Cannabis-Focused Testing Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that in August it placed a beta unit at CDX Analytics (CDX), an independent testing laboratory in Massachusetts, certified to test cannabis and hemp products for active ingredients as well as contaminants.  CDX is the first cannabis testing laboratory in Massachusetts to adopt a DNA-based microbial detection technique. The first portion of beta testing is now complete, and when the analyzer was challenged with cannabis samples containing various amounts of cannabinoids – a difficult to handle chemical compound, LexaGene’s instrument reported successful results in all runs where PCR was expected.

  • GlobeNewswire

    LexaGene to Place Beta Unit in Human Clinical Diagnostics Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has an agreement to place a beta prototype with Assurance Scientific Laboratories (ASL) in Vestavia, Alabama in August 2019.

  • GlobeNewswire

    LexaGene Approved by CDC and FDA Antibiotic Resistance Isolate Bank to Receive Samples to Test for Superbugs

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has been recognized by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank as an institution approved to receive samples for testing antibiotic resistance.

  • GlobeNewswire

    LexaGene Files Three Additional US Patents Covering Technology

    Three US patents have been recently filed, adding to the LexaGene intellectual property portfolio. The patent applications provide continuing and additional coverage to the technology of the unique sample prep DNA extraction method, the data and image processing algorithms and the fast microfluidic PCR functions of the instrument and system. This intellectual property advancement plus existing IP are continuing to provide LexaGene with a state-of-the-art, powerful and competitive low-cost platform for genetic testing.

  • GlobeNewswire

    LexaGene’s Beta Prototype Exceeds Expectations During Testing at Massachusetts Veterinary Referral Hospital

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the test results from its first beta prototype placed at the Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health. LexaGene’s test results were found to be 98% concordant with reference laboratory generated data.  On average, four samples were processed per day, with infections caused by E. coli, Proteus, and Staphylococcus.  During the study, the LexaGene test results correctly confirmed that 56% of the animals tested did not need antibiotics.

  • Baystreet

    Stocks in play: LexaGene Holdings Inc.

    Announced that LexaGene will host a webinar later this morning, to provide an investor focused overview ...